• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Kymera Therapeutics Inc.

    6/27/25 4:32:53 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KYMR alert in real time by email
    8-K
    false 0001815442 0001815442 2025-06-25 2025-06-25
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 27, 2025 (June 25, 2025)

     

     

    KYMERA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-39460   81-2992166

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    Kymera Therapeutics, Inc.

    500 North Beacon Street, 4th Floor
    Watertown, Massachusetts 02472
    (Address of principal executive offices, including zip code)

    (857) 285-5300

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trade

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0001 par value per share   KYMR   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders

    Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, each of which is described in greater detail in the Company’s Proxy Statement, filed with the Securities and Exchange Commission on April 29, 2025. The final voting results are set forth below.

    Proposal 1 – Election of Class II Director Nominees

    The shareholders of the Company elected Jeffrey Albers, J.D., MBA and Felix J. Baker, Ph.D. as Class II directors of the Company, each to hold office for a three-year term ending at the annual meeting of shareholders to be held in 2028 and until his successor has been duly elected and qualified or until his earlier death, resignation or removal. The results of the shareholders’ vote with respect to the election of the Class II directors were as follows:

     

         Votes
    For
        Votes
    Withheld
        Broker
    Non-Votes
     

    Jeffrey Albers, J.D., MBA

         55,765,189       3,142,251       2,748,381  

    Felix J. Baker, Ph.D.

         51,745,887       7,161,553       2,748,381  

    Proposal 2 – Non-Binding, Advisory Vote on Compensation of the Company’s Named Executive Officers

    The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers. The results of the shareholders’ non-binding, advisory vote with respect to such approval were as follows:

     

    Votes

    For

     

    Votes

    Against

     

    Abstain

     

    Broker
    Non-Votes

    54,364,880   4,531,413   11,147   2,748,381

    Proposal 3 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm

    The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the shareholders’ vote with respect to such ratification were as follows:

     

    Votes

    For

     

    Votes

    Against

     

    Abstain

     

    Broker
    Non-Votes

    61,644,725   4,768   6,328   0

    No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Kymera Therapeutics, Inc.
    Date: June 27, 2025     By:  

    /s/ Nello Mainolfi

          Nello Mainolfi, Ph.D.
          President and Chief Executive Officer
    Get the next $KYMR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KYMR

    DatePrice TargetRatingAnalyst
    7/3/2025$70.00Overweight
    Morgan Stanley
    6/3/2025$79.00Equal-Weight → Overweight
    Morgan Stanley
    6/3/2025$60.00Neutral → Buy
    B. Riley Securities
    6/2/2025$51.00Neutral → Buy
    BofA Securities
    5/20/2025$55.00Buy
    Stifel
    3/13/2025$52.00Buy
    Citigroup
    12/10/2024$60.00Buy
    BTIG Research
    12/6/2024$55.00Market Perform
    BMO Capital Markets
    More analyst ratings

    $KYMR
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.

      SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      7/17/25 8:12:42 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Kymera Therapeutics Inc.

      SCHEDULE 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      6/30/25 8:26:26 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Kymera Therapeutics Inc.

      8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

      6/27/25 4:55:46 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kymera Therapeutics Announces Pricing of $250 Million Public Offering

      WATERTOWN, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the pricing of its underwritten public offering of $250.8 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Kymera is selling 5,044,500 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 655,500 shares of common stock in the offering. The shares of common stock are being sold at a public offering pr

      6/26/25 11:56:15 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Proposed Public Offering

      WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in this offering are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares

      6/25/25 4:05:00 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

      Sanofi to advance Kymera's next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile Kymera is eligible for up to $975 million in collaboration milestones, double digit royalties,and may opt-in to 50/50 development and profit share of KT-485 in the U.S. WATERTOWN, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced an update to its IRAK4 partn

      6/25/25 7:05:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      7/1/25 6:41:37 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      6/30/25 8:15:05 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      6/26/25 9:00:17 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      7/1/25 6:41:37 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      6/30/25 8:15:05 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

      4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

      8/22/24 4:03:26 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Kymera Therapeutics with a new price target

      Morgan Stanley resumed coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $70.00

      7/3/25 7:49:25 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Kymera Therapeutics from Equal-Weight to Overweight and set a new price target of $79.00

      6/3/25 7:25:17 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Kymera Therapeutics from Neutral to Buy and set a new price target of $60.00

      6/3/25 7:25:12 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 4:31:20 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 1:22:39 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

      SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

      11/14/24 9:30:22 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

      WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

      5/30/25 4:01:00 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

      IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

      5/9/25 7:01:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics to Unveil New Oral Immunology Program and Report First Quarter 2025 Financial Results on May 9, 2025

      Watertown, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it will host a video webcast from 10:00 a.m. to 11:30 a.m. ET on Friday, May 9, 2025. The company will report first quarter 2025 financial results and also disclose its new oral development candidate targeting a high value undrugged target for multiple autoimmune and rheumatic diseases. Additionally, the Company will review highlights and upcoming milestones across its industry-leading immunology pipeline. To join the video call or view the li

      4/24/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KYMR
    Financials

    Live finance-specific insights

    See more
    • Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

      Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile >90% mean STAT6 degradation in blood achieved at all doses above 1.5 mg Complete STAT6 degradation achieved in both blood and skin at all MAD doses ≥50 mg KT-621 impact on Th2 biomarkers in line or superior to dupilumab with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63% KT-621 was well-tolerated with a safety profile undifferentiated from placebo, with no serious adverse events, no severe adverse events, no treatment related adverse events in more than one subject

      6/2/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

      KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in a newly disclosed preclinical chronic asthma model reversing disease progression KT-621 Phase 1 healthy volunteer SAD/MAD trial completed with data to be reported in June 2025 KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) ongoing with data expected in 4Q25 Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively WATERTOWN, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for

      5/19/25 12:15:00 PM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

      Completed KT-621 (STAT6) SAD/MAD Phase 1 healthy volunteer trial with data to be reported in June 2025 First patient dosed in KT-621 (STAT6) BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) with data expected in 4Q25 KT-579 (IRF5) new oral immunology degrader program, with broad clinical potential in rheumatic and other autoimmune diseases, expected to enter Phase 1 clinical trial in early 2026 KT-474/SAR444656 (IRAK4) Phase 2b trials in HS and AD ongoing, led by partner Sanofi; Kymera achieved a $20 million milestone payment as part of the IRAK4 collaboration in April 2025 Strategic decision made not to advance KT-295 (TYK2) into further clini

      5/9/25 7:00:00 AM ET
      $KYMR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care